How much revenue does Gongwin Biopharm Holdings make?

Gongwin Biopharm Holdings reported 36.45 million TWD in revenue for fiscal year 2025, up 13.8% from 32.04 million TWD in fiscal year 2024.

Where does Gongwin Biopharm Holdings make most of its revenue?

Hong Kong and Mainland China: 96% of revenue by region in fiscal year 2025, followed by Taiwan (4%).

What companies are similar to Gongwin Biopharm Holdings?

Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Foresee Pharmaceuticals Co., Ltd. (6576.TWO), Taho Pharma (6467.TWO), PharmaEngine, Inc. (4162.TWO), Acepodia, Inc. (6976.TWO).

Gongwin Biopharm Holdings Co., Ltd. (6617.TWO) Stock

About Gongwin Biopharm Holdings Co., Ltd.

Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs in Hong Kong, China, and Singapore. It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung cancer; PTS100, which is in Phase II clinical trials for the treatment of hepatocellular carcinoma; PTS02, which is in Phase I clinical trials for the treatment...

At a glance

Gongwin Biopharm Holdings reported revenue of 36.45 million TWD for fiscal year 2025, up 13.8% from fiscal year 2024, and net income of -114.13 million TWD. Hong Kong and Mainland China was its largest region in fiscal year 2025, with 96% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.